Simon van den Born, President of Marex Group Ltd, filed a Form 4 on November 9, 2026, disclosing the sale of 22,456 ordinary shares on November 5, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Simon van den Born, President of Marex Group Ltd (NASDAQ:MRX)
  • Transaction date: All six sale tranches were executed on November 5, 2026
  • Total shares sold: 22,456 ordinary shares disposed of across six price ranges
  • Price range: Weighted average prices ranged from $64.7773 to $69.3644 per share across the six tranches
  • Remaining beneficial ownership: 1,432,620 ordinary shares held directly following the reported transactions
  • 10b5-1 plan: Sales were effected pursuant to a Rule 10b5-1 plan entered into on June 12, 2026
  • Unvested awards included: The post-transaction share count includes 272,659 shares underlying unvested deferred bonus plan awards

Van Den Born's Six-Tranche Sale of Marex Ordinary Shares

According to the Form 4 filed with the SEC on November 9, 2026, Simon van den Born, serving as President of Marex Group Ltd (NASDAQ:MRX), disposed of ordinary shares in six separate tranches on November 5, 2026. The filing indicates all sales were made pursuant to a Rule 10b5-1 plan that van den Born entered into on June 12, 2026. The six tranches and their weighted average prices, as reported, were: 6,422 shares at $64.7773, 6,215 shares at $65.813, 4,451 shares at $66.6635, 2,046 shares at $67.6775, 3,101 shares at $68.695, and 221 shares at $69.3644.

The filing notes that each weighted average price covers transactions within a specific sub-range. For the first tranche, individual sale prices ranged from $64.17 to $65.16; for the second, from $65.17 to $66.155; for the third, from $66.1725 to $67.165; for the fourth, from $67.2075 to $68.13; for the fifth, from $68.17 to $69.0375; and for the sixth, from $69.24 to $69.61. The reporting person undertakes, according to the filing, to provide full per-price detail upon request to the issuer, any security holder, or SEC staff.

Following all reported transactions, van den Born directly holds 1,432,620 ordinary shares, the filing states. The filing clarifies that this total includes 272,659 shares underlying unvested deferred bonus plan awards previously granted to van den Born, with each award representing "a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award." No derivative securities transactions were reported. The form was signed by Scott Linsley as attorney-in-fact for Simon van den Born on November 9, 2026.

What Was Disclosed

The filing disclosed the sale of 22,456 Marex Group ordinary shares by President Simon van den Born on November 5, 2026, across six tranches at weighted average prices between $64.7773 and $69.3644, all under a Rule 10b5-1 plan established June 12, 2026.